10x is developing new technologies that increase the resolution, scale of experiments, and sample accessibility across all 3 of our major platforms: Chromium, Visium, and Xenium. In this talk, I will discuss some of the latest advancements across all 3 platforms, and showcase the joint usage of multiple platforms to uncover novel biology. In particular, I will present on some of the advantages of our new Chromium Fixed RNA Profiling, including substantially improved sensitivity over 3' V3.1, unparalleled sample and cell-scalability, and the ability to work on a variety of challenging samples, including FFPE. I will also present on our new Visium Cytassist platform and the breadth of new applications this enables. Finally, I will present the latest on our new Xenium in situ platform, including the core technological platform benefits, the latest performance, and plans for future development. I will present on a recent joint study where the same FFPE human cancer block was measured jointly using Chromium Fixed RNA Profiling, Visium Cytassist, and Xenium, to uncover novel cancer biology in this sample.